A Phase II Study of Weekly Paclitaxel Plus Gemcitabine as a Second-Line Therapy in Patients with Metastatic or Recurrent Small Cell Lung Cancer.
- Author:
Tak YUN
1
;
Heung Tae KIM
;
Ji Youn HAN
;
Sung Jin YOON
;
Hyae Young KIM
;
Byung Ho NAM
;
Jin Soo LEE
Author Information
- Publication Type:Original Article
- Keywords: Second-line; Paclitaxel; Gemcitabine; Small cell lung carcinoma
- MeSH: Asthenia; Disease Progression; Drug Therapy; Febrile Neutropenia; Humans; Neutropenia; Paclitaxel*; Recurrence; Small Cell Lung Carcinoma*; Thrombocytopenia
- From:Cancer Research and Treatment 2016;48(2):465-472
- CountryRepublic of Korea
- Language:English
- Abstract: PURPOSE: Paclitaxel (P) and gemcitabine (G) are clinically synergistic in small cell lung cancer (SCLC). We evaluated the efficacy of PG as a salvage treatment for SCLC patients whose disease progressed after a platinum-containing regimen. MATERIALS AND METHODS: Eligibility included histologically confirmed SCLC, one dimensionally measurable disease, Eastern Cooperative Oncology Group performance status 0-2, and progressive disease after platinum-based chemotherapy. Treatment consisted of P (80 mg/m2) and G (1,000 mg/m2) on days 1 and 8 of each cycle of 21 days until disease progression. RESULTS: Thirty-three patients seen between December 2005 and February 2009 were selected into this study. Thirty patients (91%) had received irinotecan-platinum, and three had received etoposide-platinum. Sixteen patients (49%) had a treatment-free interval of less than 3 months. The overall response rate was 30.3% (29.4% in sensitive relapse and 31.3% in refractory relapse). The median time to progression was 12.0 weeks and median overall survival (OS) 31.0 weeks, with a 1-year OS rate of 30.3%. Toxicities were moderate and manageable with 18.2% grade (G) 4 neutropenia, 24.2% G3 thrombocytopenia, 6.1% G3 sensory neuropathy, and 3% G3 asthenia. One patient developed febrile neutropenia. CONCLUSION: Second-line paclitaxel and gemcitabine were well-tolerated and moderately active in SCLC patients previously treated with platinum-based chemotherapy.
